Cohance Lifesciences

Price chart

Previous close

₹442.00

Open

₹435.00

Day high

₹448.55

Day low

₹429.00

Listed on NSE since 9 March 2020.

Market value

₹16,589 Cr

P/E (trailing)

364.33

EPS (trailing)

₹1.19

Price to book

4.25

Dividend yield

0.00%

Debt to equity

0.10

Profit margin

5.0%

Beta

0.59

Volume today

6.73 L

Average volume

10.66 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported. EPS before FY25 is not shown: the share count changed (a bonus, split or merger), so earlier figures would not compare.

Source: Cohance Lifesciences’s results filed with NSE, consolidated (the whole group). Net profit is the share of Cohance Lifesciences’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Cohance Lifesciences’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms (FDE); packaging and clinical trial support services; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Hyderabad

Company website · Profile: Yahoo Finance

• Cohance Lifesciences Q2 Results: Net profit plunges 80% on lower revenue, unfavourable product mix

  CNBC-TV18 · 6 Nov, 23:38

• Annual General Meeting

  Action · ex-date 6 August 2024

• Annual General Meeting

  Action · ex-date 12 December 2023

• Interim Dividend - Re 1 Per Share/Special Dividend- Rs 5 Per Share

  Dividend · ex-date 9 September 2022 · record date 12 September 2022

• Annual General Meeting

  Action · ex-date 11 August 2022

• Interim Dividend - Re 1 Per Share/Special Dividend - Re 1 Per Share

  Dividend · ex-date 13 May 2022 · record date 17 May 2022

• Interim Dividend - Re 1 Per Share/ Special Dividend - Rs 2 Per Share

  Dividend · ex-date 15 February 2022 · record date 16 February 2022

• Annual General Meeting/Dividend - Re 1 Per Share

  Dividend · ex-date 13 August 2021 · record date 17 August 2021

• Interim Dividend - Re 1 Per Share

  Dividend · ex-date 17 February 2021 · record date 18 February 2021

Source: NSE. Latest first, 8 of 9.